Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Earnings season continues, and we're here to spotlight the companies set to unveil their financial results in the next trading day, helping you prepare for the market action. Leading the charge are ...

Sionna Therapeutics (NASDAQ:SION), a clinical-stage biopharma focused on developing cystic fibrosis therapies, opened well above its initial public offering price on Friday in its first trading ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.